The Rising Influence of Rising Affluence

[DewDiligence]

98% of MYL shareholders endorse “spinversion” into a new Netherlands-based company derived from part of ABT:

http://www.sec.gov/Archives/edgar/data/69499/000119312515025838/d859790dex991.htm

As a reminder… ABT will obtain a 22% equity stake in new Mylan as consideration for ABT’s existing branded-generics business in Europe, Japan, Canada, Australia, and New Zealand. ABT is retaining its branded-generics business in India, China, Latin America, Russia, and all other emerging markets.

New Mylan will trade under the same ticker (MYL), but the transaction is expected to be a taxable event for MYL shareholders.

ABT plans to monetize its newly obtained MYL shares within the next year or so.